The weekly litigation news digest is live. Subscribe now
Combination Of Hdac Inhibitor And Anti-Pd-1 Antibody For Treatment Of Cancer - EP3270966
The patent EP3270966 was granted to Syndax Pharmaceuticals on May 1, 2024. The application was originally filed on Mar 18, 2016 under application number EP16769460A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3270966
- Application Number
- EP16769460A
- Filing Date
- Mar 18, 2016
- Status
- Granted And Under Opposition
- Mar 29, 2024
- Publication Date
- May 1, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (8) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents